Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors
about
The choreography of HIV-1 proteolytic processing and virion assemblyAtazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbonesGeneration of infectious feline immunodeficiency virus (FIV) encoding FIV/human immunodeficiency virus chimeric protease.Drug-associated changes in amino acid residues in Gag p2, p7(NC), and p6(Gag)/p6(Pol) in human immunodeficiency virus type 1 (HIV-1) display a dominant effect on replicative fitness and drug response.A multifaceted analysis of HIV-1 protease multidrug resistance phenotypesNovel HIV-1 protease inhibitors (PIs) containing a bicyclic P2 functional moiety, tetrahydropyrano-tetrahydrofuran, that are potent against multi-PI-resistant HIV-1 variantsDose-response curve slope is a missing dimension in the analysis of HIV-1 drug resistance.Altered gag polyprotein cleavage specificity of feline immunodeficiency virus/human immunodeficiency virus mutant proteases as demonstrated in a cell-based expression system.Selection of drug-resistant feline immunodeficiency virus (FIV) encoding FIV/HIV chimeric protease in the presence of HIV-specific protease inhibitorsRole of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors.Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitorsResilience to resistance of HIV-1 protease inhibitors: profile of darunavir.New approaches to HIV protease inhibitor drug design II: testing the substrate envelope hypothesis to avoid drug resistance and discover robust inhibitorsHuman Immunodeficiency Virus Gag and protease: partners in resistance.Multiple independent origins of a protease inhibitor resistance mutation in salvage therapy patients.HIV-1 protease mutations and protease inhibitor cross-resistance.Evolution of human immunodeficiency virus type 1 protease genotypes and phenotypes in vivo under selective pressure of the protease inhibitor ritonavir.GRL-079, a novel P2-Tp-THF-C5-alkylamine- and P2' -Abt-containing HIV-1 protease inhibitor, is extremely potent against multi-drug-resistant HIV-1 variants including HIVDRVRp51 and has a high genetic barrier against the emergence of resistant varian
P2860
Q27009643-282432E2-2121-4BE0-9380-ED412CE1011AQ33935276-884D3576-88BE-48FD-9C99-4BFB5256CE82Q33990752-717D8539-84A8-40CA-82AA-7442F2913F2BQ34012585-9F9CD613-165F-4BB0-B8A1-2ABEEFC74B1DQ34102058-C0719F47-7576-494B-8C7F-15AB7EAD0E09Q34737640-9895FD83-FBA3-4393-B708-E43E4A2A9609Q34937254-9206BA33-9B85-4A88-B809-590546627C59Q35024024-2D323E46-EA27-407A-8AA7-39F53FB9662EQ37036823-D752DE75-E021-459B-922E-0133C309C7F9Q37093847-F632E164-1DCF-4BFC-B35B-10D041DB9606Q37127869-3B6C47F4-D622-452E-A5DF-5017B3CFBB60Q37235740-3F658C3D-9E0C-4B70-957D-5690EF33E9BFQ37262113-B93DD8F2-13D7-445E-A626-14AB11A64853Q38032330-A2340B98-4482-4F48-830C-C38497D9B988Q42143994-5E965943-C84C-40B2-9ABA-1245322FFD3FQ42421248-6CD61D22-4B51-4F19-922D-9E17C7B0383DQ42931192-62D545B3-094A-4C51-8641-BE5333CC1955Q49792045-0923812F-C906-4F54-B617-03EFD28E011E
P2860
Selection of high-level resistance to human immunodeficiency virus type 1 protease inhibitors
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Selection of high-level resist ...... rus type 1 protease inhibitors
@ast
Selection of high-level resist ...... rus type 1 protease inhibitors
@en
Selection of high-level resist ...... rus type 1 protease inhibitors
@nl
type
label
Selection of high-level resist ...... rus type 1 protease inhibitors
@ast
Selection of high-level resist ...... rus type 1 protease inhibitors
@en
Selection of high-level resist ...... rus type 1 protease inhibitors
@nl
prefLabel
Selection of high-level resist ...... rus type 1 protease inhibitors
@ast
Selection of high-level resist ...... rus type 1 protease inhibitors
@en
Selection of high-level resist ...... rus type 1 protease inhibitors
@nl
P2093
P2860
P1476
Selection of high-level resist ...... rus type 1 protease inhibitors
@en
P2093
David Irlbeck
Terri Watkins
Wolfgang Resch
P2860
P304
P356
10.1128/AAC.47.2.759-769.2003
P407
P577
2003-02-01T00:00:00Z